Division of Nephrology, Fudan University, Minhang Hospital, Shanghai, China.
Renal Division, Department of Internal Medicine, Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Ann Palliat Med. 2021 Dec;10(12):12218-12229. doi: 10.21037/apm-21-3030.
Dialysate potassium concentration directly affects the serum potassium level and safety of hemodialysis patients. In most dialysis centers in China, a single dialysate potassium concentration is used for dialysis, but there is no data on whether this is reasonable or not.
Serum potassium values before and after dialysis in maintenance hemodialysis (MHD) patients between 2019 and 2020 were collected from 5 hemodialysis centers in Shanghai, which uniformly use dialysate with a potassium concentration (KD) of 2.0 mmol/L, and data were collected 3 times per patient for analysis. Serum potassium fluctuation was analyzed after administration of individualized KD dialysate.
In all, 1,296 MHD patients were included in the study. Predialysis serum potassium was lower than 4.5 mmol/L in 38.0% and higher than 5.5 mmol/L in 14.6% of patients. Postdialysis serum potassium was lower than 3 mmol/L in 11.3% and higher than 4 mmol/L in 10.4% of patients. Pre-dialysis serum potassium was below 4.5 mmol/L and post- dialysis serum potassium was below 3 mmol/L in 9.54% of patients. Compared with patients younger than 40 years, patients >80 years more often exhibited predialysis serum potassium below 4.5 mmol/L and Postdialysis serum potassium below 3 mmol/L. A total of 668 patients underwent a trial of hemodialysis with individualized KD dialysate. When receiving individualized KD, compared with uniform KD 2.0 mmol/L, the number of patients with postdialysis serum potassium less than 3 mmol/L significantly decreased, the following predialysis serum potassium level was not significantly different from baseline, and the proportion of patients with predialysis serum potassium less than 4.5 mmol/L and postdialysis serum potassium less than 3 mmol/L significantly decreased.
Hypokalemia and fluctuations of serum potassium are common in MHD patients. KD 2.0 mmol/L dialysate should not be used for all patients, and individualized KD dialysate for patients with low serum potassium reduces the incidence of hypokalemia.
透析液钾浓度直接影响血清钾水平和血液透析患者的安全。在中国大多数透析中心,使用单一的透析液钾浓度进行透析,但尚不清楚这种做法是否合理。
收集了 2019 年至 2020 年上海 5 家透析中心维持性血液透析(MHD)患者透析前后的血清钾值,所有患者均使用钾浓度(KD)为 2.0mmol/L 的透析液,每位患者分析 3 次数据。分析了个体化 KD 透析液给药后血清钾的波动情况。
共纳入 1296 例 MHD 患者。38.0%的患者透析前血清钾低于 4.5mmol/L,14.6%的患者透析前血清钾高于 5.5mmol/L。11.3%的患者透析后血清钾低于 3mmol/L,10.4%的患者透析后血清钾高于 4mmol/L。9.54%的患者透析前血清钾低于 4.5mmol/L,透析后血清钾低于 3mmol/L。与年龄<40 岁的患者相比,>80 岁的患者更常出现透析前血清钾低于 4.5mmol/L 和透析后血清钾低于 3mmol/L。共 668 例患者进行了个体化 KD 透析液试验。接受个体化 KD 时,与使用统一的 2.0mmol/L KD 相比,透析后血清钾低于 3mmol/L 的患者数量显著减少,以下透析前血清钾水平与基线相比无显著差异,透析前血清钾低于 4.5mmol/L 和透析后血清钾低于 3mmol/L的患者比例显著减少。
低血钾和血清钾波动在 MHD 患者中很常见。不应该为所有患者使用 2.0mmol/L KD 透析液,对于低血清钾的患者使用个体化 KD 透析液可降低低钾血症的发生率。